RxDoctor Payments Data

Mahmoud Khaimi, MD

Glaucoma Specialist · Edmond, OKNPI 1881745651

Payments from drug & device makers

$1,491,177in general payments, 2019–2025

Across 337 payments — averaging $4424.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nova Eye, Inc.$914K
  • Ellexiscience$225K
  • AbbVie$177K
  • Lumibird Medical Inc.$61K
  • Iridex Corporation$61K
  • Ocular Therapeutix, Inc.$30K
  • plus $22K from 13 others

What the payments were for

  • Consulting fees$1,021,32578%
  • Speaking & faculty fees$214,32416%
  • Travel & lodging$46,9984%
  • Food & beverage$15,1241%
  • Education$8,9741%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$381,838
Medicare patients
849
Services billed
3,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost88$35,510
SimbrinzaBrinzolamide/Brimonidine Tart66$14,728
CombiganBrimonidine Tartrate/Timolol27$13,248
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol64$9,349
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat416$9,246
Travoprost41$7,721
Prednisolone Acetate124$7,517
Brimonidine Tartrate257$7,035
Alphagan PBrimonidine Tartrate17$6,568
Latanoprost498$6,258
Methazolamide12$5,470
RhopressaNetarsudil Mesylate12$4,381
Dorzolamide Hcl230$4,033
Brinzolamide11$2,489
Timolol Maleate275$2,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$176,880$55,326132 claims
AlconSimbrinza$700$14,72866 claims
Aerie Pharmaceuticals, Inc.Rhopressa$12$4,38112 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$97$1,36911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Edmond

Where these figures come from

Is this you, or does something look wrong? →